These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21810532)

  • 1. Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
    Cauley JA; El-Hajj Fuleihan G; Arabi A; Fujiwara S; Ragi-Eis S; Calderon A; Chionh SB; Chen Z; Curtis JR; Danielson ME; Hanley DA; Kroger H; Kung AW; Lesnyak O; Nieves J; Pluskiewicz W; El Rassi R; Silverman S; Schott AM; Rizzoli R; Luckey M;
    J Clin Densitom; 2011; 14(3):240-62. PubMed ID: 21810532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FRAX® International Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.
    Cauley JA; El-Hajj Fuleihan G; Luckey MM;
    J Clin Densitom; 2011; 14(3):237-9. PubMed ID: 21810531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.
    Lewiecki EM; Compston JE; Miller PD; Adachi JD; Adams JE; Leslie WD; Kanis JA;
    J Clin Densitom; 2011; 14(3):223-5. PubMed ID: 21810529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice.
    Hans DB; Kanis JA; Baim S; Bilezikian JP; Binkley N; Cauley JA; Compston JE; Cooper C; Dawson-Hughes B; El-Hajj Fuleihan G; Leslie WD; Lewiecki EM; Luckey MM; McCloskey EV; Papapoulos SE; Poiana C; Rizzoli R;
    J Clin Densitom; 2011; 14(3):171-80. PubMed ID: 21810521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
    Lewiecki EM; Compston JE; Miller PD; Adachi JD; Adams JE; Leslie WD; Kanis JA; Moayyeri A; Adler RA; Hans DB; Kendler DL; Diez-Perez A; Krieg MA; Masri BK; Lorenc RR; Bauer DC; Blake GM; Josse RG; Clark P; Khan AA;
    J Clin Densitom; 2011; 14(3):226-36. PubMed ID: 21810530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FRAX(®) Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.
    McCloskey EV; Binkley N;
    J Clin Densitom; 2011; 14(3):181-3. PubMed ID: 21810522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus of official position of IOF/ISCD FRAX initiatives in Asia-Pacific region.
    Wu CH; McCloskey EV; Lee JK; Itabashi A; Prince R; Yu W; Li-Yu J; Chionh SB; Zhao Y; Shin CS; Gunawan T; Tsai KS; Chieng PU; Changlai SP; Chan DC; Chen JF; Tanner SB; Hans DB; Kanis JA; Chang YF; Sun ZJ; Yang RS;
    J Clin Densitom; 2014; 17(1):150-5. PubMed ID: 23916756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
    McCloskey EV; Vasikaran S; Cooper C;
    J Clin Densitom; 2011; 14(3):220-2. PubMed ID: 21810528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Official Positions for FRAX(®) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX(®) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®).
    Leib ES; Saag KG; Adachi JD; Geusens PP; Binkley N; McCloskey EV; Hans DB;
    J Clin Densitom; 2011; 14(3):212-9. PubMed ID: 21810527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Official Positions for FRAX® clinical regarding prior fractures from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
    Blank RD;
    J Clin Densitom; 2011; 14(3):205-11. PubMed ID: 21810526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Official Positions for FRAX® clinical regarding falls and frailty: can falls and frailty be used in FRAX®? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
    Masud T; Binkley N; Boonen S; Hannan MT;
    J Clin Densitom; 2011; 14(3):194-204. PubMed ID: 21810525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spine-hip T-score difference predicts major osteoporotic fracture risk independent of FRAX(®): a population-based report from CAMOS.
    Leslie WD; Kovacs CS; Olszynski WP; Towheed T; Kaiser SM; Prior JC; Josse RG; Jamal SA; Kreiger N; Goltzman D;
    J Clin Densitom; 2011; 14(3):286-93. PubMed ID: 21723768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The American Society for Bone and Mineral Research Task Force on clinical algorithms for fracture risk report.
    Burnett-Bowie SM; Wright NC; Yu EW; Langsetmo L; Yearwood GMH; Crandall CJ; Leslie WD; Cauley JA
    J Bone Miner Res; 2024 May; 39(5):517-530. PubMed ID: 38590141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of FRAX(®) model calibration on intervention rates: a simulation study.
    Leslie WD; Lix LM;
    J Clin Densitom; 2011; 14(3):272-8. PubMed ID: 21723769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total Hip Bone Area Affects Fracture Prediction With FRAX® in Canadian White Women.
    Leslie WD; Lix LM; Majumdar SR; Morin SN; Johansson H; Odén A; McCloskey EV; Kanis JA
    J Clin Endocrinol Metab; 2017 Nov; 102(11):4242-4249. PubMed ID: 29092086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fracture prediction from FRAX for Canadian ethnic groups: a registry-based cohort study.
    Leslie WD; Morin SN; Lix LM; McCloskey EV; Johansson H; Harvey NC; Kanis JA
    Osteoporos Int; 2021 Jan; 32(1):113-122. PubMed ID: 32809043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fracture burden in relation to low bone mineral density and FRAX(®) probability.
    Leslie WD; Morin S
    J Clin Densitom; 2011; 14(3):279-85. PubMed ID: 21723761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos.
    Fraser LA; Langsetmo L; Berger C; Ioannidis G; Goltzman D; Adachi JD; Papaioannou A; Josse R; Kovacs CS; Olszynski WP; Towheed T; Hanley DA; Kaiser SM; Prior J; Jamal S; Kreiger N; Brown JP; Johansson H; Oden A; McCloskey E; Kanis JA; Leslie WD;
    Osteoporos Int; 2011 Mar; 22(3):829-37. PubMed ID: 21161508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Official Positions for FRAX® clinical regarding smoking from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
    Dimai HP; Chandran M;
    J Clin Densitom; 2011; 14(3):190-3. PubMed ID: 21810524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Fracture Risk Assessment Tool in clinical practice and Fracture Risk Assessment Tool future directions.
    Zerikly R; Demetriou EW
    Womens Health (Lond); 2024; 20():17455057241231387. PubMed ID: 38529935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.